Search

This viewpoint reflects on the challenges of promoting affordable and innovative medicines while fostering a competitive environment for research and development in developing countries. We explore the life sciences industrial policies of Brazil and the United Kingdom in order to identify mechanisms and conditions that could serve as lessons to practitioners in other countries. We suggest three crucial design attributes: a strategic collaboration between a health system and the private sector, coordination and accountability mechanisms, and a network of support (that is, embeddedness). [ABSTRACT FROM AUTHOR]

Copyright of Revista Ciência & Saúde Coletiva is the property of Associacao Brasileira de Pos-Graduacao em Saude Coletiva and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Suggests changes to the flawed approach of the World Health Report 2000. Concern about data availability, as well as the methods for determining health-system responsiveness, health distribution and inequalities; Flaws in the definition of fair financing; Methodological limitations and controversies; Use of relevant publications; Controversies about the measure of health status; Concerns about the multi-component indices used; Policy context of measurement issues; Conclusion.